SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Instagram Outage Disrupts Thousands of U.S. Users 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
SAN DIEGO, Dec. 18, 2017 -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), effective prior to market open on Monday, December 18, 2017.
The Nasdaq Biotechnology Index (NBI) contains securities of Nasdaq-listed companies classified as either biotechnology or pharmaceutical, according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. The NBI is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares Nasdaq Biotechnology ETF. For more information about the NBI, visit https://indexes.nasdaqomx.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The company’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACTS
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
Kura Oncology, Inc.
(858) 500-8803
[email protected]
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
[email protected]
